Selected research
Industry Research
Helicobacter Pylori Infection Treatment Industry Research Report 2026
Market perspective
The global Helicobacter Pylori Infection Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Helicobacter Pylori Infection Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Helicobacter Pylori Infection Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Helicobacter Pylori Infection Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Helicobacter Pylori Infection Treatment include Cumberland Pharmaceuticals, Eisai Co., Bio-Rad Laboratories, F. Hoffmann-La Roche, Alpha Laboratories, Biohit, Phathom Pharmaceuticals, Redhill Biopharma and Takeda Pharmaceuticals and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Helicobacter Pylori Infection Treatment market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Helicobacter Pylori Infection Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Helicobacter Pylori Infection Treatment Market by Company
Cumberland Pharmaceuticals
Eisai Co.
Bio-Rad Laboratories
F. Hoffmann-La Roche
Alpha Laboratories
Biohit
Phathom Pharmaceuticals
Redhill Biopharma
Takeda Pharmaceuticals
AbbVie
Helicobacter Pylori Infection Treatment Segment by Type
Bismuth-quadruple Therapy
Concomitant Therapy
Levofloxacin Triple Therapy
Bismuth Therapy
High-dose Dual Therapy
Helicobacter Pylori Infection Treatment Segment by Application
Hospitals
Diagnostics Laboratories
Clinics
Helicobacter Pylori Infection Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Helicobacter Pylori Infection Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Helicobacter Pylori Infection Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Helicobacter Pylori Infection Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Helicobacter Pylori Infection Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bismuth-quadruple Therapy
- Concomitant Therapy
- Levofloxacin Triple Therapy
- Bismuth Therapy
- High-dose Dual Therapy
Applications
- Hospitals
- Diagnostics Laboratories
- Clinics
Companies covered
- Cumberland Pharmaceuticals
- Eisai Co.
- Bio-Rad Laboratories
- F. Hoffmann-La Roche
- Alpha Laboratories
- Biohit
- Phathom Pharmaceuticals
- Redhill Biopharma
- Takeda Pharmaceuticals
- AbbVie
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Helicobacter Pylori Infection Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Bismuth-quadruple Therapy
- 2.2.3 Concomitant Therapy
- 2.2.4 Levofloxacin Triple Therapy
- 2.2.5 Bismuth Therapy
- 2.2.6 High-dose Dual Therapy
- 2.3 Helicobacter Pylori Infection Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Diagnostics Laboratories
- 2.3.4 Clinics
- 2.4 Assumptions and Limitations
3 Helicobacter Pylori Infection Treatment Breakdown Data by Type
- 3.1 Global Helicobacter Pylori Infection Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Helicobacter Pylori Infection Treatment Forecasted Market Size by Type (2027-2032)
4 Helicobacter Pylori Infection Treatment Breakdown Data by Application
- 4.1 Global Helicobacter Pylori Infection Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Helicobacter Pylori Infection Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Helicobacter Pylori Infection Treatment Market Perspective (2021-2032)
- 5.2 Global Helicobacter Pylori Infection Treatment Growth Trends by Region
- 5.2.1 Global Helicobacter Pylori Infection Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Helicobacter Pylori Infection Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Helicobacter Pylori Infection Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Helicobacter Pylori Infection Treatment Market Dynamics
- 5.3.1 Helicobacter Pylori Infection Treatment Industry Trends
- 5.3.2 Helicobacter Pylori Infection Treatment Market Drivers
- 5.3.3 Helicobacter Pylori Infection Treatment Market Challenges
- 5.3.4 Helicobacter Pylori Infection Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Helicobacter Pylori Infection Treatment Players by Revenue
- 6.1.1 Global Top Helicobacter Pylori Infection Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Helicobacter Pylori Infection Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Helicobacter Pylori Infection Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Helicobacter Pylori Infection Treatment Head Office and Area Served
- 6.4 Global Helicobacter Pylori Infection Treatment Players, Product Type & Application
- 6.5 Global Helicobacter Pylori Infection Treatment Manufacturers Established Date
- 6.6 Global Helicobacter Pylori Infection Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Helicobacter Pylori Infection Treatment Market Size (2021-2032)
- 7.2 North America Helicobacter Pylori Infection Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Helicobacter Pylori Infection Treatment Market Size by Country (2021-2026)
- 7.4 North America Helicobacter Pylori Infection Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Helicobacter Pylori Infection Treatment Market Size (2021-2032)
- 8.2 Europe Helicobacter Pylori Infection Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Helicobacter Pylori Infection Treatment Market Size by Country (2021-2026)
- 8.4 Europe Helicobacter Pylori Infection Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Helicobacter Pylori Infection Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Helicobacter Pylori Infection Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Helicobacter Pylori Infection Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Helicobacter Pylori Infection Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Helicobacter Pylori Infection Treatment Market Size (2021-2032)
- 10.2 South America Helicobacter Pylori Infection Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Helicobacter Pylori Infection Treatment Market Size by Country (2021-2026)
- 10.4 South America Helicobacter Pylori Infection Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Helicobacter Pylori Infection Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Helicobacter Pylori Infection Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Helicobacter Pylori Infection Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Helicobacter Pylori Infection Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Cumberland Pharmaceuticals
- 12.1.1 Cumberland Pharmaceuticals Company Information
- 12.1.2 Cumberland Pharmaceuticals Business Overview
- 12.1.3 Cumberland Pharmaceuticals Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.1.4 Cumberland Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
- 12.1.5 Cumberland Pharmaceuticals Recent Developments
- 12.2 Eisai Co.
- 12.2.1 Eisai Co. Company Information
- 12.2.2 Eisai Co. Business Overview
- 12.2.3 Eisai Co. Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.2.4 Eisai Co. Helicobacter Pylori Infection Treatment Product Portfolio
- 12.2.5 Eisai Co. Recent Developments
- 12.3 Bio-Rad Laboratories
- 12.3.1 Bio-Rad Laboratories Company Information
- 12.3.2 Bio-Rad Laboratories Business Overview
- 12.3.3 Bio-Rad Laboratories Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.3.4 Bio-Rad Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
- 12.3.5 Bio-Rad Laboratories Recent Developments
- 12.4 F. Hoffmann-La Roche
- 12.4.1 F. Hoffmann-La Roche Company Information
- 12.4.2 F. Hoffmann-La Roche Business Overview
- 12.4.3 F. Hoffmann-La Roche Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.4.4 F. Hoffmann-La Roche Helicobacter Pylori Infection Treatment Product Portfolio
- 12.4.5 F. Hoffmann-La Roche Recent Developments
- 12.5 Alpha Laboratories
- 12.5.1 Alpha Laboratories Company Information
- 12.5.2 Alpha Laboratories Business Overview
- 12.5.3 Alpha Laboratories Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.5.4 Alpha Laboratories Helicobacter Pylori Infection Treatment Product Portfolio
- 12.5.5 Alpha Laboratories Recent Developments
- 12.6 Biohit
- 12.6.1 Biohit Company Information
- 12.6.2 Biohit Business Overview
- 12.6.3 Biohit Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.6.4 Biohit Helicobacter Pylori Infection Treatment Product Portfolio
- 12.6.5 Biohit Recent Developments
- 12.7 Phathom Pharmaceuticals
- 12.7.1 Phathom Pharmaceuticals Company Information
- 12.7.2 Phathom Pharmaceuticals Business Overview
- 12.7.3 Phathom Pharmaceuticals Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.7.4 Phathom Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
- 12.7.5 Phathom Pharmaceuticals Recent Developments
- 12.8 Redhill Biopharma
- 12.8.1 Redhill Biopharma Company Information
- 12.8.2 Redhill Biopharma Business Overview
- 12.8.3 Redhill Biopharma Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.8.4 Redhill Biopharma Helicobacter Pylori Infection Treatment Product Portfolio
- 12.8.5 Redhill Biopharma Recent Developments
- 12.9 Takeda Pharmaceuticals
- 12.9.1 Takeda Pharmaceuticals Company Information
- 12.9.2 Takeda Pharmaceuticals Business Overview
- 12.9.3 Takeda Pharmaceuticals Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.9.4 Takeda Pharmaceuticals Helicobacter Pylori Infection Treatment Product Portfolio
- 12.9.5 Takeda Pharmaceuticals Recent Developments
- 12.10 AbbVie
- 12.10.1 AbbVie Company Information
- 12.10.2 AbbVie Business Overview
- 12.10.3 AbbVie Revenue in Helicobacter Pylori Infection Treatment Business (2021-2026)
- 12.10.4 AbbVie Helicobacter Pylori Infection Treatment Product Portfolio
- 12.10.5 AbbVie Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst